Are there long-term benefits of donepezil in Alzheimer's disease?

Black, Sandra E.; Szalai, John P.
November 2004
CMAJ: Canadian Medical Association Journal;11/9/2004, Vol. 171 Issue 10, p1174
Academic Journal
Discusses research being done on long-term donepezil treatment in patients with Alzheimer's disease. Reference to a study by C. Courtney and colleagues, published in a 2004 issue of the "Lancet" journal; Reason behind a decline in subjects who participated in the trial; Implications of problems in patient recruitment and retention for the study.


Related Articles

  • Galantamine worth it for AD in many countries.  // PharmacoEconomics & Outcomes News;9/25/2004, Issue 462, p5 

    Discusses research on the potential of galantamine treatment to delay the need for full-time care among patients with Alzheimer's disease. Reference to a study by J. Caro et al. published in a 2004 issue of "Drugs and Aging"; Method used in estimating the long-term economic impact of...

  • Side by Side Traveling the Road--and Sharing the Load--of Alzheimer's's Disease. Neustadt, Gail K. // ASHA Leader;05/15/2001, Vol. 6 Issue 9, p4 

    Reports on the author's experience in coping with her husband's Alzheimer's Disease (AD). Observations before her husband was diagnosed with AD; Linguistic deficits experienced by her husband; Communication intervention designed to allow the patient to communicate at an adult level.

  • Chapter Ten: An Alzheimer's Case History. Driscoll, Eileen H. // Alzheimer's: A Handbook for the Caretaker;2004, p114 

    This article presents a case history illustrating the progress of Alzheimer's disease. The caregiver and family in this case history pretty much do everything right. The names and places are fictitious. Mary is the patient. Her husband and primary caregiver is John. Their children are Joe, Bob...

  • TauRx Launches Pivotal LMTX Program in Pick's, Alzheimer's. Moran, Nuala // BioWorld International;9/12/2012, Vol. 17 Issue 37, p1 

    The article reports that a 180-patient Phase III trial of the tau aggregation inhibitor, LNTX, in Pick's disease, has been launched by TauRx Therapeutics Ltd. It relates that Pick's disease is an early onset form of dementia with characteristics similar to Alzheimer's disease. It describes the...

  • The Glutamatergic System and Alzheimer’s Disease: Therapeutic Implications. Butterfield, D. Allan; Pocernich, Chava B. // CNS Drugs;2003, Vol. 17 Issue 9, p641 

    Alzheimer’s disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer’s disease is present in nearly half of individuals aged...

  • Skausmas sergant Alzheimerio liga: sensoriniai, emociniai ir kognityviniai aspektai. Kaubrys, G. // Neurologijos Seminarai;2007, Vol. 11 Issue 4, p242 

    Differential disorders of sensory-discriminative, affective-motivational, and cognitive-evaluative aspects of pain perception in Alzheimer's disease patients are reviewed in this article. While disfunctions of lateral and medial pain systems and corresponding sensory and affective components of...

  • Las pausas en el discurso de individuos con demencia tipo Alzheimer. Estudio de casos. Rodríguez, Jhennifer // Revista Lengua y Habla;ene-dic2013, Vol. 17, p253 

    Pause is a prosodic parameter used in oral statements, and has been used in this research study to analyze the discourse of two Alzheimer's patients. This disorder does not only manifest clinically, but in communicative situations and discourses that can be observed through pauses, for example....

  • NICE approves drugs for Alzheimer's disease. Kmietowicz, Zosia // BMJ: British Medical Journal (International Edition);01/27/2001, Vol. 322 Issue 7280, p190 

    Reports that health authorities in England and Wales have been told to end rationing of drugs to treat Alzheimer's disease, and make them available to all patients in whom the drugs might slow the progression of the disease. Guidance issued by the National Institute for Clinical Excellence...

  • 3D Texture Analysis of Corpus Caliosum Based on MR Images in Patients With Alzheimer's Disease and Mild Cognitive Impairment. Weifang Liu; Xu Wang; Hong Xia // Applied Mechanics & Materials;2014, Issue 533, p415 

    Objective: This study investigated three-dimensional (3D) texture as a possible diagnostic marker of Alzheimer's disease (AD). Methods: T1-weighted MRI of 18 AD patients, 18 Mild Cognitive Impairment (MCI) patients and 18 normal controls (NC) were selected. 3D Texture parameters of the corpus...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics